Results 51 to 60 of about 9,985 (145)

Micafungin in vitro aktivitása több mint 300 darab, különböző betegekből származó candida izolátum ellen

open access: yes, 2010
A Candida genus speciesei közül a legjelentősebb a C. albicans, mert ez okoz leggyakrabban opportunista fertőzéseket emberekben, melyeknek a száma napjainkban fokozatosan nő.
Domán, Marianna
core  

Micafungin use in a UK tertiary referral hospital

open access: yes, 2018
Objectives: Here we sought to describe the real-life usage of micafungin in a UK tertiary referral hospital. Methods: A prospective, non-interventional, observational surveillance study was performed in a large teaching hospital do we need ‘in a large ...
Aliyu, Sani H.   +5 more
core   +1 more source

Simple and robust LC-MS/MS analysis method for therapeutic drug monitoring of micafungin [PDF]

open access: yes, 2018
Aim: To develop a simple and robust LC-MS/MS method to quantify concentrations of micafungin in human plasma for pharmacokinetic studies and therapeutic drug monitoring.
Boonstra, Jasper M; id_orcid   +11 more
core   +1 more source

Evaluation of an Antifungal Stewardship Initiative Targeting Micafungin at an Academic Medical Center

open access: yes, 2023
Delays in the treatment of proven invasive fungal disease have been shown to be harmful. However, empiric treatment for all patients at risk of infection has not demonstrated benefit.
Zerelda Esquer Garrigos   +8 more
core   +1 more source

Results of the use of micafungin in newborns

open access: yes, 2019
Invasive candidiasis is a common and serious infection in premature newborns. Preventing and treating fungal infections is very important to improve the prognosis of premature infants.

core   +2 more sources

Micafungin in the treatment of candiduria: A case series

open access: yes, 2016
Echinocandin antifungal agents are not routinely recommended for the treatment of candiduria due to low urine concentrations and a paucity of clinical data supporting this indication.
Lauren E. Kane, Katie M. Muzevich
core   +1 more source

Micafungin Concentrations in the Plasma and Burn Eschar of Severely Burned Patients

open access: yes, 2012
Micafungin concentrations in plasma and burn eschar after daily intravenous infusion (1 h) of micafungin (200 to 300 mg) were investigated for six patients with severe burns. Micafungin treatment was initiated more than 72 h after the burn injuries.
Yotaro Shinozawa   +10 more
core   +1 more source

Population pharmacokinetics of micafungin in neonates and young infants

open access: yes, 2010
Micafungin is an echinocandin with potent activity against Candida spp. Hematogenous Candida meningoencephalitis (HCME) is a frequent complication of disseminated Candida infection in premature infants.
M. Roy   +17 more
core   +1 more source

Clinical efficacy and safety of micafungin, a novel echinocandin antifungal drug, in pulmonary aspergillosis in a postmarketing setting

open access: yes, 2010
今回われわれは,呼吸器領域で実施された市販後調査の成績をもとに,慢性肺アスペルギルス症(chronic pulmonary aspergillosis:CPA)に対するmicafungin(MCFG)の有効性および安全性を検討した。 35施設から収集された109例のうち,CPAの診断が確認できなかった症例や併用薬の規定に違反した症例計18例を除く91例を有効性解析対象例とした。このうち,評価不能であった11例を除く80例の有効率は63.8%(51/80例)であった ...
網谷, 良一   +7 more
core  

Response to other antifungal drugs of micafungin-sensitive mutants.

open access: yes, 2013
(A) Representative examples of micafungin-sensitive mutants that showed varying levels of sensitivity to AmB. Cells were spotted onto plates containing YES or YES plus 20 µg/ml AmB and incubated at 27°C for 4 days.
Yuki Yamada (104430)   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy